Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Edward B Garon, Tudor-Eliade Ciuleanu, Oscar Arrieta, Kumar Prabhash, Konstantinos N Syrigos, Tuncay Goksel, Keunchil Park, Vera Gorbunova, Ruben Dario Kowalyszyn, Joanna Pikiel, Grzegorz Czyzewicz, Sergey V Orlov, Conrad R Lewanski, Michael Thomas, Paolo Bidoli, Shaker Dakhil, Steven Gans, Joo-Hang Kim, Alexandru Grigorescu, Nina Karaseva, Martin Reck, Federico Cappuzzo, Ekaterine Alexandris, Andreas Sashegyi, Sergey Yurasov, Maurice Pérol
  • The Lancet, August 2014, Elsevier
  • DOI: 10.1016/s0140-6736(14)60845-x

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1016/s0140-6736(14)60845-x

The following have contributed to this page: Dr Federico Cappuzzo